ERBB2 and cancer: To show that the effect of sunitinib is not limited to a single target cell line and to a single antibody, we confirmed the ADCC inhibitory effect of the drug on three additional HER2 positive cancer cell lines (Fig. 4c) and in assays in which trastuzumab was replaced with the anti-EGFR antibody cetuximab (Fig. 4d).